Navigation Links
Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
Date:3/26/2012

ant improvement in tardive dyskinesia symptoms for the subjects while receiving the 50mg once-daily dose. These subjects had a significant reduction in tardive dyskinesia symptoms at the end of two weeks of active treatment vs. the end of two weeks of placebo (difference in LS mean of 4.2 for the 50mg period vs. the placebo period, p-value=0.002). As expected, the 12.5mg dosing group was not statistically better during the active treatment period than during the placebo period (difference in LS mean of 0.4 for the 12.5mg period vs. placebo period, p-value=0.68).

The improvement in symptomology is also evidenced by the significant improvement in AIMS scores over baseline levels relative to placebo, excluding the one site. NBI-98854 reduced the average baseline AIMS score by 9.2 points in the 50mg period (p-value=0.0004) vs. a reduction of 4.9 points in the 12.5mg period and 4.7 for the placebo periods. A responder analysis also showed improvement in both the investigator reported Clinical Global Impression-Tardive Dyskinesia and the patient reported Patient Global Impression of Change.

When including the data from the site in question, this study did not meet the pre-specified primary endpoint of reducing the AIMS scores during active treatment periods. The efficacy results from the entire study population showed a non-significant reduction in tardive dyskinesia at the end of two weeks of active treatment vs. the end of two weeks of placebo (difference in LS mean of 1.1 for the 50mg period vs. the placebo period (n=15), p-value=0.42) (difference in LS mean of 0.7 for the 12.5mg period vs. placebo period (n=17), p-value=0.59).

The tables below summarize the primary endpoint as well as the responder analyses for all clinical sites as well as the post-hoc analysis. All Clinical Trial Sites Baseline(mean)Placebo12.5mg50mgAbnormal Involuntary Movement Scale (LS Means)14.7

9.9

9.1

8.8 

 


'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
2. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
3. Neurocrine Mourns the Passing of Founder and Board Member Wylie Vale, Ph.D.
4. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
6. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
8. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 PCCA received ... ( http://bit.ly/1382OkS ) program seal for best ... The program highlights medical practices, materials and goods ... friendly." Children affected by autism often ... be exacerbated by ingredients found in food and ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has ... (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava ... by 2016. The North America ... while Europe claims approximately 27% ...
(Date:12/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... added to the NASDAQ Biotechnology Index (NBI). The ... effective upon market open on December 22, 2014. ... to track the performance of a set of ... or pharmaceutical according to the Industry Classification Benchmark. ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (NYSE Amex: ... "Company"), a developer, manufacturer and distributor of botanical ... announced that the Company has received a significant ... since it won a major one-year contract bid ...
... Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces ... phase 2 trial, in patients with advanced non-small ... there was a survival advantage in the subset ... of epithelial tumors) receiving entinostat in combination with ...
Cached Medicine Technology:China Botanic Sees Strong Initial Demand from Guangzhou Military Region 2China Botanic Sees Strong Initial Demand from Guangzhou Military Region 3Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients 2Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients 3Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients 4
(Date:12/15/2014)... Cancer researchers have just published an important ... deadly malignant pleural mesothelioma. Surviving Mesothelioma has just posted ... Click here to read it now. , Doctors ... and New York’s Langone Medical Center performed complete genetic ... in an effort to pinpoint the genes that are ...
(Date:12/15/2014)... West Palm Beach, FL (PRWEB) December 15, 2014 ... Urgent Care , knows that holidays can be a daze ... accidents. From slips and falls while decking halls, to burns ... are plenty of holiday hazards that can happen at any ... reason for pain, MD Now has made a list of ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... In support of high-quality independent peer ... state laws that may have unintended consequences through ... of public health policy. , The position paper, ... Independent Review, contends that state legislation that restricts ... determinations can result in subpar outcomes for both ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... at about 15 months of age to prevent heart disease ... bmj.com today. , High cholesterol which runs ... two in every 1000 people and causes very high levels ... blood. It carries a high risk of death from coronary ...
... expand options, reduce costs for ECC training, ... Heart,Association research has supported education and training programs ... lives each year.,Now, healthcare providers have more ways ... as the organization introduces a,significantly expanded eLearning program. ...
... Hospital Group to Automate and Connect 165 ... Physicians Across 36 Medical Groups, ... the leading provider of clinical software, connectivity and,information solutions that ... Health System (WPAHS) has selected,Allscripts as its Electronic Health Record ...
... to Make a Blood Donation to Honor Blood ... Collectors and Support Their Communities, LAKE ... of September 16-22, 2007, blood collection centers across the,United States ... and Fenwal, Inc. This celebratory week recognizes the important,service blood ...
... requires lifelong dependence on insulin injections, researchers say , ... insulin-linked gene can cause permanent neonatal diabetes, say American ... mutations in 21 people from 16 families. , Permanent ... affects infants and leads to lifelong dependence on insulin ...
... Saturday,September 15 will mark the first national "Short ... advocacy group, will be holding special,events in several ... City and,Washington, DC, musicians with psoriasis will headline ... have a,cookout; and across the country, people with ...
Cached Medicine News:Health News:Experts propose cholesterol tests at 15 months of age 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 3Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 4Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 2Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 3Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 4Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 2Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 3Health News:Gene Mutations May Cause Rare Neonatal Diabetes 2Health News:Psoriasis Cure Now Rolls Out First National 'Short Sleeve Day' Saturday 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: